Q-omics provides the consensus-scored ZSCAN31 profile across patient tissues and cancer cell-line models. ZSCAN31 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZSCAN31 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, ZSCAN31 RNA expression shows 20,204 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where ZSCAN31 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZSCAN31 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZSCAN31 survival associations across molecular data types. ZSCAN31 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZSCAN31 RNA expression–survival associations across cancer types. High ZSCAN31 expression shows unfavorable associations in LIHC, but favorable associations in KIRC, READ, ACC, MESO and LAML. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZSCAN31 RNA expression.
This table summarizes ZSCAN31 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZSCAN31. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZSCAN31 shows lower tumor expression in THCA and STAD and higher tumor expression in LIHC, HNSC, CHOL and KIRC. The THCA box plot shows higher ZSCAN31 RNA expression in normal versus tumor tissue (log2 FC = −0.815, t-test p < 0.001).
This table shows molecular features associated with ZSCAN31 in patient tissues and cancer cell lines. In patient samples, ZSCAN31 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZSCAN31 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SKIN.
